Metoclopramide nasal spray is effective in symptoms of gastroparesis in diabetics compared to conventional oral tablet

Neurogastroenterology and Motility

Volumn 26, Issue 4, 2014, Pages 521-528

  Parkman, H P ^a   Carlson, M R ^b   Gonyer, D ^c  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b entreMeDica Inc   (United States)

^c Evoke Pharma   (United States)

Author keywords

Diabetes; Dopamine antagonist; Gastroparesis; Metoclopramide; Prokinetic agent

Indexed keywords

METOCLOPRAMIDE; PLACEBO; ANTIEMETIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DROWSINESS; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; STOMACH PARESIS; TABLET; TREATMENT OUTCOME; VOMITING; ADOLESCENT; AGED; CLINICAL TRIAL; COMPLICATION; DIABETES COMPLICATIONS; GASTROPARESIS; INTRANASAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; DIABETES COMPLICATIONS; FEMALE; GASTROPARESIS; HUMANS; MALE; METOCLOPRAMIDE; MIDDLE AGED; YOUNG ADULT;

EID: 84896373389     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12296     Document Type: Article

References (11)

1. Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 2004; 127: 1592-622.
2. Parkman HP, Fass R, Foxx-Orenstein AE. Treatment of patients with diabetic gastroparesis. Gastroenterol Hepatol 2010; 6: 1-16.
3. Hejazi RA, McCallum RW. Diabetic gastroparesis: a review of medical treatments. Prac Gastroenterology 2009; 24: 10-20.
4. Metoclopramide (Reglan). Med Lett Drugs Ther 1982;24:67-9.
5. Scaglione F, Scanni A, Tomirotti M, Dimaiuta M, Ferrari P, Fraschini F. Pharmacokinetics and bioavailability of metoclopramide nasal spray versus metoclopramide intravenous in healthy volunteers and cancer patients. Arzneimittelforschung 1993; 43: 986-8.
6. Tomirotti M, Dimaiuta M, Confalonieri M, Scanni A. Efficacy and tolerability of nasally administered compared to parenterally administered metoclopramide in the symptomatic treatment of chemotherapy-induced emesis in cancer outpatients. A controlled clinical study. Support Care Cancer 1994; 2: 389-92.
7. Perkel MS, Hersh T, Moore C, Davidson ED. Metoclopramide therapy in fifty-five patients with delayed gastric emptying. Am J Gastroenterol 1980; 74: 231-6.
8. Ormrod D, Goa KL. Intranasal metoclopramide. Drugs 1999; 58: 315-22.
9. Fass R, Pieniaszek HJ, Thompson JR. Pharmacokinetic comparison of orally-disintegrating metoclopramide with conventional metoclopramide tablet formulation in healthy volunteers. Aliment Pharmacol Ther 2009; 30: 301-6.
10. Shafer D, Butterfield M, Pamer C, Mackay AC. Tardive dyskinesia and metoclopramide use: effects of cisapride market withdrawal. J Am Pharm Assoc 2004; 44: 661-5.
11. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther 2009; 31: 11-9.